Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
In the third quarter, Griffin and Citadel more than tripled its stake in Viking Therapeutics (NASDAQ: VKTX) . Griffin isn't the only one enthusiastic about this clinical-stage drugmaker. Wall Street analysts are sticking their necks out and predicting big gains around the corner. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Recently, B. Riley analyst Mayank Mamtani initiated coverage of Viking Therapeutics with a buy rating. He gave the stock a $109 price target that implies a gain of about 105% from recent prices. It's hard to overstate the level of demand out there for drugs that reduce appetites and blood sugar by activating glucagon-like peptide-1 (GLP-1) receptors. Sales of semaglutide, which Novo Nordisk markets as Wegovy for weight loss and as Ozempic for diabetes, reached $19.7 billion during the first nine months of 2024. Semaglutide has been on the market since 2018, and it could soon be overtaken by Eli
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Here's Why VKTX Stock Plummeted 18% on Wednesday [Yahoo! Finance]Yahoo! Finance
- Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $102.00 price target on the stock.MarketBeat
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXAccesswire
VKTX
Earnings
- 10/23/24 - Beat
VKTX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form 4
- VKTX's page on the SEC website